Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C391/00—Compounds containing selenium
  • C07C391/02—Compounds containing selenium having selenium atoms bound to carbon atoms of six-membered aromatic rings
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/111—Aromatic compounds
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
  • A61K31/10—Sulfides; Sulfoxides; Sulfones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
  • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
  • C07D213/32—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Definitions

• the present invention relates to the compound represented by formula ( I ) as a PPAR (Peroxisome Proliferator Activated Receptor) ligand and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof, which can be used for the treatment of obesity, hyperlipidemia, arteriosclerosis and diabetes, and a pharmaceutical composition, a cosmetic composition, an strengthening agent, a memory improving agent, a therapeutic agent for dementia and Parkinson's disease, a functional food and a feed composition containing the same.
• PPAR Peroxisome Proliferator Activated Receptor
• PPAR Peroxisome Proliferator Activated Receptor
• PPAR ⁇ , PPAR ⁇ and PPAR ⁇ have tissue specific functions in vivo and different regions for expression.
• PPAR ⁇ is mainly expressed in the heart, kidney, skeletal muscle and large intestine in human (MoI. Pharmacol. 1998, 53, pl4-22., Toxicol. Lett. 1999, 110, pll9- 127, J " . Biol. Chem.
• PPAR ⁇ is expressed in the skeletal muscle at a low level but mainly expressed in the adipose tissue to induce the adipocyte differentiation and to store energy as the form of fat, and is involved in homeostatic regulation of insulin and glucose (Moll. Cell. 1999, 4, p585-594., p597-609., p611-617).
• PPAR ⁇ is preserved evolutionarily in mammals including human and vertebrates including rodents and sea squirts.
• PPAR ⁇ The first PPAR ⁇ found in Xenopus laevis was known as PPAR ⁇ (Cell 1992, 68, p879-887) and PPAR ⁇ found in human was named differently as NUCl (MoI. Endocrinol. 1992, 6, pl634-1641) , PPAR ⁇ (Proc. Natl. Acad. Sci. USA 1994, 91, p7355-7359) , NUCl (Biochem. Biophys. Res. Commun. 1993, 196, p671-677) , FAAR (J " . Bio. Chem. 1995, 270, p2367-2371), ect, but they have been renamed as PPAR ⁇ recently.
• NUCl MoI. Endocrinol. 1992, 6, pl634-1641
• PPAR ⁇ Proc. Natl. Acad. Sci. USA 1994, 91, p7355-7359
• NUCl Biochem. Biophys. Res
• PPAR ⁇ is known to exist in chromosome 6p21.1-p21.2.
• PPAR ⁇ mRNA is found in various cells but the level is lower than those of PPAR ⁇ or PPARy (Endocrinology 1996, 137, p354-366., J " . Bio. Chem. 1995, 270, p2367-2371, Endocrinology 1996, 137, p354-366) .
• the previous studies confirmed that PPAR ⁇ plays an important role in the reproductive cell expression (Genes Dev. 1999, 13, pl561-1574) and has physiological functions of differentiating neuronal cells (J " . Chem.
• PPAR ⁇ activates the expression of key gene involved in ⁇ -oxidation in fatty acid catabolism and uncoupling proteins (UCPs) , the gene involved in energy metabolism, which brings the effect of improving obesity (Nature 2000, 406, p415-418, Cell 2003, 113, pl59-170, PLoS Biology 2004, 2, pl532-1539) .
• the activation of PPAR ⁇ increases the HDL level, improves type 2 diabetes without weight changes (Proc. Natl. Acad. Sci.
• PPAR ⁇ is involved in the mitochondria generation and the muscle fiber conversion in muscles to enhance endurance.
• Muscles have fatty acid catabolism muscle fiber (Type I ) that enhances endurance and glycoclastic muscle fiber (Type II) that enhances power.
• Fatty acid catabolism muscle fiber (Type I ) which is responsible for enhancing endurance is red because it has plenty of mitochondria and myoglobin.
• glycoclastic muscle fiber (Type II) which is responsible for enhancing power is white.
• Type I muscle fiber was increased significantly, in addition to the increase of myoglobin, electron transport system enzymes (cytochrome c, cytochrome c oxidases II and IV) and fatty acid ⁇ oxidase. Therefore, constant running time and distance were respectively 67% and 92% increased, compared with wild type rats (PLoS Biology, 2004, 2:e294).
• Synthetic PPAR ⁇ ligands developed so far have less selectivity, compared with other PPAR ⁇ and PPARy ligands.
• the early selective ligand was L-631033, developed by Merk (J. Steroid Biochem. MoI. Biol. 1997, 63, pl-8) , which was produced by introducing a functional group being able to fix side chain based on its natural fatty acid morphology.
• the same research team reported later more effective ligand L- 165041 (J. Med. Chem. 1996, 39, p2629-2654), in which the compound known as a leukotriene agonist is functioning to activate human PPAR ⁇ .
• the PPAR ⁇ selective ligand GW501516 ( [2 -methyl-4- [ [ [4- methyl-2- [4- (trifluoromethyl) phenyl] -1, 3-thiazol-5- yl] methyl] sulfanyl] phenoxy] acetic acid), developed by GlaxoSmithKline, exhibits much better physiological effect than any other ligands previously developed (Proc. Natl. Acad. Sci. USA 2001, 98, p5306-5311) .
• the GW501516 has excellent affinity (1-10 nM) to PPAR ⁇ , and excellent selectivity to PPAR ⁇ or PPAR ⁇ as well, which is at least 1000 times the selectivity of earlier ligands.
• the thiazole compound represented by formula A as a PPAR ⁇ selective activator has been described in WO 2001-00603 and WO 2002-62774 applied by Glaxo group and WO 2003-072100 applied by Eli Lilly.
• R 1 is CF 3 or F
• R 1 ⁇ is H, CH 3 or Cl
• R" 1 is H, CH 3 or CH 2 CH 3
• R" 11 is H, alkyl or aryl alkyl .
• the present invention relates to the compound represented by formula ( I ) having activity to peroxisome proliferator activated receptor PPAR (referred as 1 PPAR' hereinafter), and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof, a preparing method of the same, and a pharmaceutical composition, a cosmetic composition, an strengthening agent, a memory improving agent, a therapeutic agent for dementia and Parkinson's disease, a functional food and a feed composition containing the same.
• formula ( I ) having activity to peroxisome proliferator activated receptor PPAR (referred as 1 PPAR' hereinafter), and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof, a preparing method of the same, and a pharmaceutical composition, a cosmetic composition, an strengthening agent, a memory improving agent, a therapeutic agent for dementia and Parkinson's disease, a functional food and a feed composition containing the same.
• R >- A ⁇ > 0"B [Wherein, A is S or Se ; B is H or Ri is aryl selected from the following structures ;
• R 2 is H, C1-C8 ;
• R 3 is H, C1-C8 alkyl or halogen;
• R 4 and R 5 are independently H, C1-C8 alkyl;
• R 6 is H, C1-C8 alkyl, C2-C7 alkenyl, alkali metal or alkali earth metal;
• Rn and Ri 2 are independently H, C1-C8 alkyl or halogen;
• R 2 i is H, halogen, C1-C7 alkyl, heterocyclic group or C1-C7 alkoxy;
• m and n are independently integers of 1-4;
• p is an integer of 1-5;
• q is an integer of 1-4;
• r is an integer of 1- 3;
• s is an integer of 1-5; and alkyl and alkoxy of R 2 , R 3 ,R 4 , R 5 , R 6 , Ri 1 , Ri 2 and R 21 can be substituted with one or more
• R 1 of the aryl compound represented by formula ( I ) having activity to peroxisome proliferator activated receptor (PPAR) is preferably aryl selected from the following structures;
• R 2 is C1-C8 alkyl substituted or non-substituted with
• R 4 and R 5 are independently H or C1-C5 alkyl substituted or non-substituted with halogen;
• R 6 is H, C1-C7 alkyl, alkali metal or alkali earth metal;
• Rn and R 12 are independently H, C1-C5 alkyl substituted with one or more fluorines or fluorine;
• R 21 is H, halogen, C1-C5 alkyl substituted or non-substituted with halogen or C1-C5 alkoxy substituted or non-substituted with halogen;
• p is an integer of 1-5;
• q is an integer of 1-4; and
• s is an integer of 1-5.
• R 2 of the compound represented by formula ( I ) can be further substituted with methyl, ethyl, n-propyl, i-propyl, n- butyl, i-butyl or t-butyl and benzyl of R 2 can be further substituted with fluorine, chlorine, methyl, ethyl, n-propyl, i-propyl, t-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, pentafluoroethyl, methoxy, ethoxy, propoxy, n-butoxy, t-butoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy and pentafluoroethoxy;
• R 3 is H, methyl, ethyl, n-propyl, i-propyl, n-butyl, t- butyl,
• R 4 and R 5 are independently H, methyl, ethyl, n-propyl, i- propyl, n-butyl, t-butyl, n-pentyl, 2-ethylhexyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl or pentafluoroethyl ;
• R 6 is H, methyl, ethyl, n-propyl, i-propyl, n-butyl, t- butyl, n-pentyl, 2-ethylhexyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, pentafluoroethyl, ethenyl, 2- propenyl, 2-butenyl, 3-butenyl, Li + , Na + , K + , Ca 2+ , or Mg 2+ ;
• R 11 and Ri 2 are independently H, methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 2-ethylhexyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, pentafluoroethyl, fluorine or chlorine.
• novel compound of the present invention can be prepared by the following reaction formula.
• Prot herein is phenol protecting group, which can be Cl- C4 lower alkyl, allyl, alkylsilyl, alkylarylsilyl or tetrahydropyranyl; alkyl and alkoxy of R 2 , R3 ,R 4 , R 5 , R 6 , Rn, Ri 2 and R 2 i can be substituted with one or more halogens or Cl- C5 alkylamine; m and n are independently integers of 1-4; p is an integer of 1-5; q is an integer of 1-4; r is an integer of 1-3; s is an integer of 1-5; Xi is bromine atom or iodine atom; X 2 and X 3 are independently chlorine atom, bromine atom, iodine atom or leaving group having reactivity with nucleophilic substitution. However, the case that R 2 is H and A is S is excluded. ] Hereinafter, the preparing method of the invention is described in detail.
• the anhydride solvent used in this process is selected from the group consisting of such single solvents as diethylether, tetrahydrofuran, hexane and heptane and mixed solvents comprising at least two of these solvents. It is more preferred to select diethylether, tetrahydrofuran or the mixed solvent comprising diethylether and tetrahydrofuran as the anhydride solvent. And it is most preferred to select a polar solvent, which can be tetrahydrofuran.
• Grignard reagent used herein can be selected from the group consisting of methyl, ethyl, ⁇ -propyl, iso-propyl, n- butyl, sec-butylmagnesiumchloride (R 2 MgCl) and alkylmagnesiurabromide (R 2 MgBr) .
• iso- propylmagnesiumchloride ( (CH 3 ) 2 CHMgCl) is most preferred.
• the reaction temperature depends on a solvent, but it is generally set at -20 ⁇ 40 ° C and preferably at 0 ° C ⁇ room temperature (25 ° C).
• the reaction time depends on the reaction temperature and a solvent, but it is generally 10 - 60 minutes and preferably 10 - 30 minutes. [Halogen- lithium substitution and S or Se introduction]
• the organic metal reagent used for halogen- lithium substitution can be selected from the group consisting of n- butyl lithium, sec-butyl lithium and tert-butyl lithium. Among these compounds, tert-butyl lithium is most preferred. S or Se with fine particles is preferred, which is added as dissolved in anhydride tetrahydrofuran or added directly.
• the reaction temperature depends on a solvent, but is generally set at -78 ⁇ 25 ° C.
• the reaction temperature for halogen-metal substitution is preferably -75 " C and the temperature for S or Se introduction is -75 ⁇ room temperature (25 ° C) .
• the halogen-metal substitution reaction takes 10 - 30 minutes and the S or Se introduction reaction takes 30 - 120 minutes .
• Halogen of the compound represented by formula (III) is selected from the group consisting of chlorine, bromine and iodine. And among these, chlorine is most preferred.
• the reaction temperature depends on a solvent, but it is generally set at -78 ⁇ 25 ° C, more preferably at 0 ⁇ 10 ° C.
• the reaction time is generally 10 - 120 minutes and preferably 10
• the compound represented by formula (IV) is preferably reacted with the compound generally used as phenol protecting group in the presence of base .
• the phenol protecting group is exemplified by C1-C4 lower alkyl, allyl, alkylsilyl such as trimethylsilyl, tert- butyldiphenylsilyl, triisopropylsilyl and tert- butyldimethylsilyl, alkylarylsilyl and tetrahydropyranyl .
• tert-butyl group tetrahydropyranyl group and silyl group are preferred.
• the aprotic polar solvent used in this process is selected from the group consisting of N 1 N-dimethylformamide, N 1 N-dimethylacetamide, dimethylsilfoxide, acetonitrile, acetone, ethylacetate, carbon tetrachloride, chloroform and dichloromethane .
• the ether herein can be selected from the group consisting of tetrahydrofuran, dioxane, dimethoxyethane , diethyleneglycoldimethylether and triethyleneglycoldimethylether.
• the aromatic hydrocarbon is exemplified by benzene, toluene and xylene.
• the aprotic polar solvent is preferred and particularly N/N-dimethylformamide, chloroform or dichloromethane is more preferred.
• the base herein is amine including pyridine, triethylamine, imidazole, 2V,iV-dimethylaminopyridine .
• bases such bases as sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate are used.
• imidazole and potassium carbonate are more preferred.
• the tetrahydropyranyl protecting group is obtained by catalytic reaction of 3 , 4-dihydro-2H-pyran with alkyl or allyltriphenylphosphonium bromide .
• the reaction temperature depends on a solvent, but it is generally set at -10 ⁇ 80 ° C, more preferably at 0 ⁇ room temperature (25 ° C) .
• the reaction time depends on the reaction temperature and a solvent, but generally it takes from one hour to one day. It is more preferred to finish the reaction within 4 hours.
• the anhydride solvent used in this process is selected from the group consisting of such single solvents as diethylether, tetrahydrofuran, hexane and heptane and mixed solvents comprising at least two of these solvents. It is more preferred to select diethylether, tetrahydrofuran or the mixed solvent comprising diethylether and tetrahydrofuran as the anhydride solvent .
• the strong alkali used for the ⁇ -proton extraction is selected from the group consisting of potassium tert-butoxide (t-BuOK) , lithium diisopropyl amide (LDA) , n-butyl lithium, sec-butyl lithium and tert-butyl lithium, and among these compounds, lithium diisopropyl amide (LDA) is most preferred.
• the electrophile reacted with the nucleophile of thio or selenoether is any compound that can be easily obtained by the conventional method known to those in the art or easily produced according to the methods described in references, which is exemplified by those compounds harboring highly reactive halogen, aldehyde or ketone group and is either dissolved in an anhydride solvent for the addition or added directly for the reaction.
• the reaction temperature depends on a solvent but is generally -78 ⁇ 25 ° C. It is more preferred to perform the ⁇ - proton extraction reaction in the presence of a strong alkali at -75 ° C at which electrophile is added. Then, the temperature is raised slowly to room temperature (25 ° C) .
• the reaction time differs from each reaction stage. For example, the ⁇ -proton extraction by a strong alkali takes 10-30 minutes and the reaction with electrophile takes 30-90 minutes.
• the compound represented by formula (VIII) is obtained by eliminating the phenol protecting group from the compound represented by formula (VII) .
• the polar solvent used in this process is selected from the group consisting of N, iV-dimethylformamide, N, N- dimethylacetamide, dimethylsilfoxide, acetonitrile, acetone, ethylacetate, carbon tetrachloride, chloroform and dichloromethane .
• the ether herein can be selected from the group consisting of tetrahydrofuran, dioxane, dimethoxyethane and diethyleneglycoldimethylether .
• the alcohol can be methanol or ethanol .
• the aromatic hydrocarbon is exemplified by benzene, toluene and xylene.
• the polar solvent is preferred and particularly tetrahydrofuran is more preferred.
• trimethylsilyliodide, ethanethioalcoholsodium salt, lithiumiodide, aluminum halide, boron halide or Lewis acid such as trifluoroacetate is used, and to eliminate the silyl protecting group such as tritnethylsilyl, terfc-butyldiphenylsilyl, triisopropylsilyl and tert-butyldimethylsilyl, fluoride such as tetrabutylammoniumfluorine (Bu 4 N + F " ) , halogen acid (hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid) or potassium fluoride is used.
• reaction temperature depends on a method and a solvent but is generally 0 ⁇ 120 ° C and preferably 10 ⁇ 25 ° C .
• the reaction time depends on the reaction temperature, but generally it takes from 30 minutes to one day. It is more preferred to finish the reaction within 2 hours.
• the compound represented by formula (VIII) is preferably reacted with halogenacetate alkylester or alkylhalogenacetate alkylester in the presence of base.
• the halogenacetate alkylester or alkylhalogenacetate alkylester is the general compound that can be easily obtained.
• the compound that can not be easily obtained is prepared by bromination of alkylacetate alkylester.
• the halogen herein is exemplified by chlorine atom, bromine atom and iodine atom.
• the solvent used in this process can be a soluble single solvent selected from the group consisting of N 1 N- dimethylformamide, N, iV-dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethanol and methanol or a mixed solvent prepared by mixing these compounds with 1-10% water.
• the most preferred solvent is a mixed solvent prepared by mixing acetone or dimethylsulfoxide with 1-5% water.
• the base used in this process is not limited as long as it does not have a bad influence on the reaction, regardless of strong or weak, which is exemplified by alkali metal hydride such as sodium hydride and lithium hydride, alkali earth metal hydride such as potassium hydride, alkali metal hydroxide such as sodium hydroxide and potassium hydroxide, and alkali metal carbonate such as lithium carbonate, potassium carbonate, potassium bicarbonate and cesium carbonate. Among these compounds, alkali metal carbonate is preferred, and potassium carbonate is more preferred.
• the reaction temperature is not limited but up to the boiling point of a solvent. However, high temperature is not preferred to inhibit side reactions. The preferable reaction temperature is 0 ⁇ 90 ° C .
• the reaction time differs from the reaction temperature but is generally 30 minutes - 1 day and preferably 30 - 120 minutes.
• the solvent used in this process is a soluble solvent that can be mixed with water, for example alcohols such as methanol and ethanol .
• the base used in this process is an aqueous solution prepared by mixing alkali metal hydroxide such as lithium hydroxide, sodium hydroxide and potassium hydroxide with water at the concentration of 0.1-3 N, considering the type of carboxylic acid alkali salt.
• the acid used to obtain the compound represented by formula (X) as a carboxylic acid form is preferably acetic acid aqueous solution, sodium hydrogen sulfate (NaHSO 4 ) aqueous solution or 0.1-3 N hydrochloric acid aqueous solution, and 0.5 M NaHSO 4 is more preferred.
• the reaction is preferably performed at a low temperature in order to inhibit side reactions, which is generally 0 ° C - room temperature.
• the reaction time depends on the reaction temperature but is generally 10 minutes - 3 hours and more preferably 30 minutes - 1 hour.
• the preferable reaction temperature is 0°C and the preferable reaction time is 1 - 2 hours .
• the compound represented by formula (X) is prepared by allyl ester salt substitution from the compound represented by formula (IX) using alkali metal salt or alkali earth metal salt of 2-ethylhexanoate and a metal catalyst in an organic solvent .
• the solvent used in this process is an anhydride organic solvent selected from the group consisting of chloroform, dichloromethane and ethylacetate .
• the metal catalyst used in this process is paladiumtetrakistriphenylphosphine and the preferable content thereof is 0.01 - 0.1 equivalent.
• the reaction is preferably performed at a low temperature in order to inhibit side reactions, which is generally 0°C - room temperature.
• the reaction time depends on the reaction temperature but is generally 10 minutes - 3 hours and more preferably 30 minutes - 1 hour.
• Such salt compound can be easily separated by centrifugation or ion exchange resin.
• the obtained metal salt compound of formula (X) is much easier to separate than the salt compound prepared by process F-I (hydrolysis) .
• the resultant Y type compound of formula ( D is a very important material as a PPAR protein ligand. This compound contains chiral carbon, suggesting that it also includes stereoisomer thereof.
• the present invention includes the aryl compound represented by formula ( D and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof .
• the aryl compound represented by formula ( J) and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof of the present invention can be effectively used as a composition for PPAR activator.
• the aryl compound represented by formula ( D and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof of the present invention can activate PPAR, so that they can be effectively used as a pharmaceutical composition for the prevention and treatment of arteriosclerosis, hyperlipidemia, obesity, diabetes, dementia or Parkinson's disease and for lowering cholesterol, for strengthening muscles, for improving endurance and memory, and as a composition for functional food and beverages, food additives, functional cosmetic and animal feeds .
• the aryl compound represented by formula ( I) and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof of the present invention can be used for the functional cosmetic composition for prevention and improvement of obesity and for the functional cosmetic composition for strengthening muscle and enhancing endurance.
• the functional cosmetic composition for strengthening muscle and enhancing endurance can be formulated as ointment, lotion or cream to be applied on the body part before/after exercise and can be used for a long term to bring the wanted effect.
• the aryl compound represented by formula ( D and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof of the present invention can be formulated as ointment and be applied on the body part to prevent or treat diabetes or diabetic foot ulcer, so-called diabetic ulcer.
• the present invention provides a pharmaceutical composition, a functional food adjuvant, a functional drink, a food additive and a feed composition for the prevention and treatment of arteriosclerosis, dementia and Parkinson's disease, for strengthening muscle, for enhancing endurance or for improving memory containing the PPAR activator as an active ingredient.
• the present invention also provides a screening method of an activator for the prevention and treatment of arteriosclerosis, dementia and Parkinson's disease, strengthening muscle, enhancing endurance and improving memory, which comprises the steps of adding a PPAR activator candidate to PPAR; and measuring the activity of PPAR.
• the pharmaceutically acceptable salt herein includes all the pharmaceutically acceptable organic salts that are able to form salt with carboxylic acid of the compound of formula ( D and inorganic salts such as alkali metal ions and alkali earth metal ions, which are exemplified by Li + , Na + , K + , Ca 2+ and Mg 2+ .
• the therapeutic effective dose of the compound represented by formula ( I) and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof of the present invention can be determined according to the type of compound, administration method, target subject and target disease but is determined based on the conventional medicinal standard.
• the preferable dose of the compound represented by formula ( D is 1-100 mg/kg(body weight) /day.
• the administration frequency can be once or several times a day within the allowed one day dosage.
• the composition of the present invention can be administered orally or parenterally and be used in general forms of pharmaceutical formulation.
• the composition of the present invention can be formulated as tablets, powders, dried syrups, chewable tablets, granules, capsules, soft capsules, pills, drinks, sublinguals, etc.
• the tablets of the present invention can be administered to a subject by a method or pathway that delivers the effective dose of the tablet with bioavailability, which is oral pathway. And the administration method or pathway can be determined according to the characteristics, stages of the target disease and other conditions.
• the composition of the present invention can additionally include pharmaceutically acceptable excipients. The content and characteristics of the excipient can be determined by the solubility and chemical properties of the selected tablet, administration pathway and standard pharmaceutical practice.
• Example 4 Preparation of compound S4 [Process C] 489 mg (1 mmol) of the compound S2 was dissolved in 20 ml of anhydride tetrahydrofuran and the temperature was lowered to -78 ° C 1.8 ml (1.8 M 1 2.0 equivalent) of lithium diisopropyl amide (LDA) was slowly added thereto. Then, 270 ⁇ i (2.0 mmol) of 2-chloro-5-fluorobenzylbromide was added to the reaction solution, and the temperature was slowly raised to room temperature.
• LDA lithium diisopropyl amide
• the PPAR ⁇ activity of the compound represented by formula (I) of the present invention was confirmed by transfection assay. In addition, the selectivity to PPAR subtypes, PPAR ⁇ and PPARy, was examined. Cytotoxicity was tested by MTT assay and in vivo activity was investigated by animal experiment.
• CV-I cells were used in this assay.
• the cells were inoculated in a 96-well plate containing DMEM supplemented with 10% FBS, DBS (delipidated) and 1% penicillin/streptomycin and cultured in a 37 ° C 5% CO 2 incubator.
• the experiment was performed according to the steps of inoculation, transfection, sample treatment and confirmation.
• CV-I cells were inoculated in a 96 well-plate (5000 cells/well) , followed by transfection 24 hours later.
• PPARs plasmid DNA Full length PPARs plasmid DNA, reporter DNA confirming PPARs activity owing to its luciferase activity, ⁇ -galactosidase DNA providing information on transfection efficiency, and transfection reagent were used for the transfection.
• Samples were dissolved in dimethylsulfoxide (DMSO) , which were treated to the cells via media at different concentrations. After culturing the cells in the incubator for 24 hours, the cells were lysed by using lysis buffer. Luciferase activity and ⁇ -galactosidase activity were measured with Luminometer and a microplate reader. The obtained values of luciferase were modified by the values of ⁇ -galactosidase. A graph was made with those values and EC 50 was calculated.
• DMSO dimethylsulfoxide
• the compounds of the present invention are highly selective to PPAR ⁇ .
• the activity of the compound of the present invention to PPAR ⁇ was 2 nM-200 nM. MTT assay
• MTT assay was performed to test cytotoxicity of the compound represented by formula ( D of the present invention.
• MTT is a yellow substance soluble in water, but when it is introduced into a living cell, it turns into a purple insoluble crystal by dehydrogenase in mitochondria.
• Cytotoxicity can be confirmed by measuring OD 550 after dissolving MTT in dimethylsulfoxide . The experiment was performed as follows.
• CV-I cells were inoculated in a 96-well plate (5000 cells/well) .
• the cells were cultured in a 37°C5% CO 2 incubator for 24 hours, and treated with samples at different concentrations. Then, the cells were cultured for 24 hours again, to which MTT reagent was added. After culturing for 15 minutes, the generated purple crystals were dissolved in dimethylsulfoxide. Optical density was measured with a microplate reader to confirm cytotoxicity.
• the compound represented by formula ( D was confirmed not to have cytotoxicity even at the concentration of 100-1000 times the EC 50 value to PPAR.
• Obesity inhibitory effect An animal test using mice was performed to confirm the in vivo effect of the compound of the present invention. C57BL/6 (SLC Co.) mice at 8 weeks were used. To induce obesity, feeds containing 35% fat were given. While feeding such high- fat feeds for 60 days, vehicle, S14, S46 and S106 (10 mg/kg/day) were orally administered. As a result, only 31% of the S14 treated group mice showed weight increase, compared with the vehicle group, and 43% and 37% of the S46 treated group and the S106 treated group showed weight increase respectively. Diabetes improving effect GTT (glucose tolerance test) was performed to confirm the diabetes improving effect of the compound of the present invention.
• GTT glucose tolerance test
• Glucose (1.5g/Kg) was intra-abdominally administered to the mice pre-treated orally with samples for 57 days. Blood glucose was measured every hour. Fasting blood glucose was lower in the S14, S46 and S106 (10 mg/Kg/day) treated groups than in control . The group treated with the compound of the present invention exhibited rapid blood glucose decrease in 20 - 40 minutes and glucose clearance in 100 minutes. In the meantime, the blood glucose level was not recovered to normal in the vehicle treated group even after 120 minutes. The above results indicate that the compounds S14, S46 and S106 had diabetes improving effect.
• Muscle endurance strengthening and muscle function enhancing effect An animal test was performed to confirm muscle endurance strengthening and muscle function enhancing effect of the composition of the present invention. Most muscles are generated in developmental stage. Thus, S14, S46 and S106 (10mg/Kg/day) were treated to pregnant mice in the period of either pregnancy or lactation or both pregnancy and lactation. Weight gaining and growth rate were not much different between fetuses of the control group and the treatment group. Muscles were observed after removing skin. As a result, muscles of the treatment group were red, unlike the control. ATPase staining and immunostaining were performed. As a result, type I muscle fiber was increased in the treatment group. The role of the changes of the muscle fiber in the enhancement of muscle endurance and muscle function was investigated by using treadmill test. As a result, running time was much extended in the treatment group, compared with the control. [Table 7] Results of muscle endurance test
• the therapeutic effect of the compound of the present invention on dementia and Parkinson' s disease based on the memory improving effect thereof was investigated using brain disease animal model (C57BL/6 mice at 10 weeks) .
• LPS was injected into the mouse brain to construct brain disease animal model.
• the mice were divided into four groups according to the administration and exercise.
• the exercise was performed with treadmill at the speed of 2 meter/min for the first 5 minutes, at 5 meter/min for 5 minutes, at 8 meter/min for 5 minutes and at 20 meter/min for the last 5 minutes.
• Morris water maze test was performed.
• Table 8 the therapeutic effect of the compound of the invention on dementia and Parkinson's disease via memory enhancement by the compound and exercise was confirmed in the brain disease animal model .
• the novel compound of the present invention is functioning as a PPAR activator ligand, so that it is a highly promising candidate for a pharmaceutical composition for the prevention and treatment of cardiovascular disease, diabetes, obesity, dementia and Parkinson's disease, for lowering cholesterol level, for strengthening muscles or for improving memory; a functional food adjuvant, a functional drink, a food additive, a functional cosmetic composition and a feed composition.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• Polymers & Plastics (AREA)
• Neurology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Biomedical Technology (AREA)
• Food Science & Technology (AREA)
• Neurosurgery (AREA)
• Nutrition Science (AREA)
• Mycology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Zoology (AREA)
• Animal Husbandry (AREA)
• Psychiatry (AREA)
• Physical Education & Sports Medicine (AREA)
• Child & Adolescent Psychology (AREA)
• Endocrinology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Hospice & Palliative Care (AREA)
• Emergency Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Psychology (AREA)
• Epidemiology (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39468091

Family Applications (1)

Country Status (10)

Families Citing this family (19)

Family Cites Families (9)

• 2007
  • 2007-12-01 CN CNA2007800439924A patent/CN101595089A/zh active Pending
  • 2007-12-01 RU RU2009125232/04A patent/RU2444514C2/ru not_active IP Right Cessation
  • 2007-12-01 AU AU2007326114A patent/AU2007326114B2/en not_active Ceased
  • 2007-12-01 CN CN201210050537XA patent/CN102584685A/zh active Pending
  • 2007-12-01 WO PCT/KR2007/006170 patent/WO2008066356A1/en not_active Ceased
  • 2007-12-01 CN CN2012105795307A patent/CN103086936A/zh active Pending
  • 2007-12-01 CN CN2012100504273A patent/CN102863362A/zh active Pending
  • 2007-12-01 JP JP2009539189A patent/JP5455636B2/ja not_active Expired - Fee Related
  • 2007-12-01 KR KR1020070124052A patent/KR100951653B1/ko not_active Expired - Fee Related
  • 2007-12-01 US US12/517,156 patent/US8519145B2/en active Active
  • 2007-12-01 BR BRPI0716272-3A2A patent/BRPI0716272A2/pt not_active IP Right Cessation
  • 2007-12-01 CA CA002669639A patent/CA2669639A1/en not_active Abandoned
  • 2007-12-01 EP EP07851173A patent/EP2102155A4/de not_active Withdrawn

Also Published As

Similar Documents

Legal Events